Project STAVANGER, Unzyme Laboratories’ comprehensive neural enhancement initiative, has successfully completed Phase II clinical trials. The results exceed our projections and position us for Phase III expansion in early 2023.
Exceptional Outcomes
Phase II enrolled 847 participants across our clinical network, evaluating both safety and efficacy of our neural enhancement protocols over a 12-month period. The findings are compelling:
Cognitive Performance:
- 52% average improvement in working memory tasks
- 38% faster processing speed on standardized assessments
- Sustained benefits throughout the study period
- No decline observed at 12-month follow-up
Safety Profile:
- No serious adverse events related to intervention
- Mild, transient side effects in 12% of participants (resolved within 72 hours)
- No unexpected findings in comprehensive neurological monitoring
“These results validate our core hypothesis,” explained Dr. Elena Voss, Principal Investigator for STAVANGER. “Meaningful, lasting cognitive enhancement is achievable with current technology. We’re not speculating about future possibilities—we’re demonstrating present capabilities.”
What STAVANGER Means
Project STAVANGER represents our most ambitious research initiative to date. Named for the Norwegian city where our founding team first conceived the project, STAVANGER aims to develop safe, effective methods for enhancing human cognitive function across multiple domains.
Unlike narrow interventions targeting specific deficits, STAVANGER approaches cognition as an integrated system. Our protocols enhance the brain’s underlying processing capabilities, producing improvements that generalize across tasks and contexts.
Path Forward
Phase III trials will begin in Q1 2023, expanding enrollment to approximately 3,000 participants across diverse populations. We anticipate regulatory submissions beginning in 2024, with potential commercial availability by 2025.
We recognize the profound implications of this research. Enhanced cognition touches every aspect of human experience—work, relationships, creativity, problem-solving. We approach this responsibility with appropriate gravity while remaining committed to expanding human potential.
Acknowledgments
This achievement reflects the dedication of hundreds of researchers, clinicians, and participants. Special recognition goes to our trial volunteers, whose courage and commitment advance cognitive enhancement for everyone.
Progress continues. The mind expands.